Literature DB >> 9229578

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.

J L Masferrer1, P C Isakson, K Seibert.   

Abstract

The NSAIDs are potent anti-inflammatory and analgesic agents. It is now believed that the NSAIDs exert their therapeutic activity through the inhibition of COX-2 at the site of inflammation. Unfortunately, these compounds are equally capable of inhibiting constitutively expressed COX-1 in tissues such as the gastrointestinal tract and kidney, which results in serious, mechanism-based toxicities that limit the drug's therapeutic utility. With the identification of selective COX-2 inhibitors, alternatives to traditional NSAID therapy should be available that will provide clinical usefulness with reduced toxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9229578     DOI: 10.1016/s0889-8553(05)70252-1

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  16 in total

1.  Inhibition of beta-catenin translocation in rodent colorectal tumors: a novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer.

Authors:  W A Brown; S A Skinner; D Vogiagis; P E O'Brien
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.

Authors:  O Morteau; S G Morham; R Sellon; L A Dieleman; R Langenbach; O Smithies; R B Sartor
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation.

Authors:  W A Brown; S A Skinner; C Malcontenti-Wilson; D Vogiagis; P E O'Brien
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 4.  Future directions in thrombolysis.

Authors:  J T Willerson; P Zoldhelyi
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

5.  Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.

Authors:  Juan Anguita; Swapna Samanta; Shobana K Ananthanarayanan; Beatriz Revilla; Gregory P Geba; Stephen W Barthold; Erol Fikrig
Journal:  FEMS Immunol Med Microbiol       Date:  2002-11-15

6.  Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.

Authors:  S Aggarwal; N Taneja; L Lin; M B Orringer; A Rehemtulla; D G Beer
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

7.  Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.

Authors:  Li Ma; Piero del Soldato; John L Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

8.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

9.  Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.

Authors:  Wei Li; Hong-he Zhang; Ru-jun Xu; Guang-chao Zhuo; Ye-qing Hu; Juan Li
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

10.  Ex vivo effects of lysine clonixinate on cyclooxygenases in rat lung and stomach preparations.

Authors:  A M Franchi; G Di Girolamo; A R De los Santos; M L Marti; M A Gimeno
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.